Time & Date: 2 September, 08:30 – 09:30 CEST
Chairpersons: S. Sivaprasad UK & M. Barakat USA
Speakers & Presentations:
S. Sivaprasad UK
08:30 Welcome
L. Frizziero ITALY
08:32 Diabetic retinopathy screening: a comparison study between handheld fundus camera and table-top fundus camera on 1182 eyes
R. Tadayoni FRANCE
08:38 Phase 2 Study of OCS-01 OPTIREACH® (Soluble Nanoparticle) Technology Topical Dexamethasone Eye Drops for Diabetic Macular Edema (DME): Subgroup Analyses in Patients with Lower Baseline Visual Acuity
S. Sivaprasad UK
08:44 Evaluation of intravitreal aflibercept treatment effectiveness in UK routine clinical practice for patients with diabetic macular edema: Year 2 results of the DRAKO study
M. Barakat USA
08:50 Suprachoroidal Delivery of RGX-314 Gene Therapy for Diabetic Retinopathy: The Phase II ALTITUDE™ Study
J. Nogués Castell SPAIN
08:56 Retinal Neurodegeneration and retinal vessel changes assessed by Optical Coherence Tomography Angiography in type 1 Diabetes Mellitus. A large scale OCTA study
A. Olvera-Barrios UK
09:02 Is timing everything? The impact of intravitreal anti-VEGF for diabetic macular edema treatment on development of proliferative diabetic retinopathy using weighted cumulative exposure analysis.
H. Mehta AUSTRALIA
09:08 A Phase IV randomized clinical trial of intravitreal aflibercept monotherapy versus intravitreal aflibercept combined with targeted retinal laser to areas of peripheral retinal ischemia for diabetic macular edema in eyes with severe non-proliferative diabetic retinopathy (LADAMO)
V. Sheth USA
09:14 Three Year Outcomes from the PALADIN Phase IV Study: A Comparison of Anatomical Metrics Pre- and Post-0.19 mg Fluocinolone Acetonide Treatment and their Relationship to Efficacy and Treatment Burden Outcomes
All Faculty
09:20 Discussion
